Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial
Abstract Background Clinical outcomes of patients with osteosarcoma remain unsatisfactory, with little improvement in a 5-year overall survival over the past three decades. There is a substantial need for further research and development to identify and develop more efficacious agents/regimens in or...
Main Authors: | Nut Koonrungsesomboon, Nuttapong Ngamphaiboon, Natavudh Townamchai, Pimpisa Teeyakasem, Chaiyut Charoentum, Pimlak Charoenkwan, Rungrote Natesirinilkul, Lalita Sathitsamitphong, Touch Ativitavas, Parunya Chaiyawat, Jeerawan Klangjorhor, Suradej Hongeng, Dumnoensun Pruksakorn |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-06751-2 |
Similar Items
-
Surgical outcomes of extracorporeal irradiation and re-implantation in extremities for high grade osteosarcoma: A retrospective cohort study and a systematic review of the literature
by: Dumnoensun Pruksakorn, et al.
Published: (2019-02-01) -
Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma
by: Parunya Chaiyawat, et al.
Published: (2019-06-01) -
Expression profiling of DNA methyl transferase I (DNMT1) and efficacy of a DNA-hypomethylating agent (decitabine) in combination with chemotherapy in osteosarcoma
by: Parunya Chaiyawat, et al.
Published: (2020-12-01) -
Prognostic score for life expectancy evaluation of lung cancer patients after bone metastasis
by: Dumnoensun Pruksakorn, et al.
Published: (2018-03-01) -
Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma
by: Parunya Chaiyawat, et al.
Published: (2017-10-01)